Replies to post #237393 on Biotech Values

[vinmantoo]

Patients (n=350) enrolled in the TIVO-3 study were randomized 1:1 to receive either FOTIVDA or sorafenib. The main efficacy outcome measure was progression-free survival (PFS), assessed by a blinded independent radiology review committee. Other efficacy endpoints were overall survival (OS) and objective response rate (ORR).

Median PFS was 5.6 months (95% CI: 4.8, 7.3) in the FOTIVDA arm (n=175) compared with 3.9 months (95% CI: 3.7, 5.6) for those treated with sorafenib (HR 0.73; 95% CI: 0.56, 0.95; p=0.016). Median OS was 16.4 (95% CI: 13.4, 21.9) and 19.2 months (95% CI: 14.9, 24.2), for the FOTIVDA and sorafenib arms, respectively (HR 0.97; 95% CI: 0.75, 1.24). The ORR was 18% (95% CI: 12%, 24%) for the FOTIVDA arm and 8% (95% CI: 4%, 13%) for the sorafenib arm.

So the PFS & ORR were better than Sorafenib but the OS was worse. Why the big jump?

[DewDiligence]

Korea’s LG Chem acquires AVEO for_$15.00_cash—a 43% premium to yesterday’s close:

https://finance.yahoo.com/news/lg-chem-acquire-aveo-oncology-083000671.html

The nominal deal value is $566M.

[DewDiligence]

Kyowa Kirin—>testing cancer drug, tivozanib as_an eyedrop for AMD:

https://www.prnewswire.com/news-releases/kyowa-kirin-announces-acceptance-of-abstract-for-presentation-at-the-association-for-research-in-vision-and-ophthalmology-annual-meeting-2024-302106101.html

I’m pretty skeptical that an eyedrop can work for a back-of-the-eye-disease like AMD, but it would be awesome if it did.

Tivozanib, under the brand name Fotivda, was FDA-appoved for RCC in 2021 (#msg-162474260).